Related references
Note: Only part of the references are listed.
Article
Clinical Neurology
Barbara Kornek et al.
Summary: The study found that patients on anti-CD20 therapy had lower rates of SARS-CoV-2-specific antibodies compared to controls, but antibody levels were lower in patients without detectable B cells. In contrast, B-cell depleted patients showed a more pronounced T-cell response to the Wuhan strain and Delta variant compared to nondepleted patients.
ANNALS OF NEUROLOGY
(2022)
Article
Clinical Neurology
Gabriel Bsteh et al.
Summary: This study compared the humoral immune response and safety of SARS-CoV-2 vaccines in patients with multiple sclerosis (pwMS) and healthy controls (HCs). The results showed that the majority of pwMS had seroconversion, but the immune response was reduced by immunosuppressive disease-modifying treatments (DMTs).
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Edouard Januel et al.
Summary: Recent studies suggest a lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination in patients treated with anti-CD20 and fingolimod. This study evaluated cases of COVID-19 occurring after vaccination among patients with MS and NMO, finding mild severity in cases reported. The results emphasize the need for a third COVID-19 vaccine dose for anti-CD20 treated patients and call for further prospective studies on vaccine efficacy in MS and NMO patients.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Infectious Diseases
Hannah Hussey et al.
Summary: This study aimed to assess whether the SARS-Cov-2 Omicron variant infection reduces the risk of severe disease. Using a proxy marker (RTD), the researchers found that patients without this marker had a lower risk of hospital admission, and complete vaccination provided protection against admission. However, accurately assessing the virulence of immune escape variants remains challenging due to under-ascertainment of reinfections.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
News Item
Medicine, General & Internal
[Anonymous]
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Article
Medicine, General & Internal
N. Andrews et al.
Summary: A large case-control study in England found that immunity to the Omicron variant was very low and less than that to the Delta variant 20 weeks after the second vaccine dose, regardless of the initial vaccine type. A booster dose of one of the mRNA vaccines improved efficacy to approximately 65%, but protection waned over a 10-week period.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Clinical Neurology
G. Bsteh et al.
Summary: This study aimed to determine the frequency and distribution of COVID-19 mortality risk factors in multiple sclerosis patients. The results showed that the proportion of patients at high risk of COVID-19 mortality is below 1%, with the vast majority of these high-risk patients not receiving any disease-modifying treatment.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Maria P. Sormani et al.
Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.
ANNALS OF NEUROLOGY
(2021)
Article
Clinical Neurology
Gabriel Bsteh et al.
Summary: This study found that the seropositivity rate of SARS-CoV-2 antibodies is significantly lower in pwMS receiving immunosuppressive treatments, especially in patients using anti-CD20 monoclonal antibodies. The humoral immunity remains stable after SARS-CoV-2 infection in MS patients.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Article
Medicine, General & Internal
Sachin P. Gadani et al.
Summary: This study found robust T cell responses in individuals with multiple sclerosis on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow-up studies are needed to determine if this translates to protection against COVID-19 infection.
Editorial Material
Medicine, General & Internal
Gabriel Bsteh et al.
Review
Cell Biology
Steve Pascolo
Summary: By September 2021, twenty-one anti-COVID-19 vaccines have been approved worldwide, with utilization expected to help bring an end to the pandemic. In addition to traditional vaccine formats such as inactivated viruses and protein-based vaccines, new formats like recombinant adenovirus, DNA, and mRNA have been validated. Western countries primarily reserve or use protein vaccines, adenovirus vaccines, and mRNA vaccines, with mRNA vaccines being seen as the superior option in terms of speed and effectiveness.
Article
Biochemistry & Molecular Biology
Sokratis A. Apostolidis et al.
Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.
Article
Multidisciplinary Sciences
Gabriel Bsteh et al.
Summary: This study investigated the prevalence and outcomes of COVID-19 in multiple sclerosis patients, and found that overall, exposure to disease-modifying treatment and immunosuppressive therapy were not significantly associated with COVID-19 outcomes, providing reassuring evidence for individual risk assessment in MS patients.
Letter
Clinical Neurology
Giulio Disanto et al.
Article
Clinical Neurology
Maria Pia Sormani et al.
Summary: This study evaluated the impact of disease-modifying therapies on Covid-19 severity in patients with multiple sclerosis through a pooled-analysis of two large cohorts. The results showed that anti-CD20 therapies were significantly associated with severe Covid-19, while interferon indicated a decreased risk.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Medicine, General & Internal
Maria Pia Sormani et al.
Summary: This study found that anti-CD20 treatment and fingolimod in MS patients led to reduced humoral response to mRNA vaccines. mRNA-1273 vaccine resulted in significantly higher antibody levels compared to BNT162b2, suggesting it may be preferred for patients under certain treatments.
Article
Clinical Neurology
Deja R. Rose et al.
Summary: Studies have shown reduced serological response to vaccines in patients on anti-CD20 agents, but limited data exist on vaccine efficacy in patients on disease modifying therapy (DMT). This study aimed to investigate breakthrough COVID-19 cases in vaccinated people with multiple sclerosis on DMT. Results showed that a small percentage of fully vaccinated patients on DMT were diagnosed with COVID-19, with most cases on anti-CD20 therapy and only a few requiring hospitalization. Further research is needed to analyze the risk of COVID-19 in patients on different therapies, especially in the context of emerging variants.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL
(2021)
Article
Clinical Neurology
Anat Achiron et al.
Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Clinical Neurology
Celine Louapre et al.
Article
Clinical Neurology
Floor C. Loonstra et al.
MULTIPLE SCLEROSIS JOURNAL
(2020)
